ライフサイエンスコーパス: attenuated virus

1 he earliest vaccines were based on the live, attenuated virus.

2 ible for affecting the immune response to an attenuated virus.

3 etermined to be 10(3) focus-forming units of attenuated virus.

4 r the phenotype of virulence to an otherwise attenuated virus.

5 on in enhancing the safety profile of a live-attenuated virus.

6 the extent of the mutations present in this attenuated virus.

7 erate, through codon pair deoptimization, an attenuated virus.

8 n through either inactivated virions or live attenuated virus.

9 s occurred in three parallel passages of the attenuated virus.

10 specific immunity rather than infection with attenuated virus.

11 eplication defective, possibly behaving like attenuated viruses.

12 for dengue vaccine development based on live-attenuated viruses.

13 , more cells are initially infected with the attenuated viruses.

14 aning to toxoid/protein vaccines and to live attenuated viruses.

15 ed after infection with virulent compared to attenuated viruses.

16 a means to produce replication-defective or attenuated viruses.

17 ment of vaccination strategies based on live-attenuated viruses.

18 ion of all mutations in the entire genome of attenuated viruses.

19 vian influenza viruses and produce partially attenuated viruses.

20 inent neurotropism associated with all three attenuated viruses.

21 fection is best achieved by vaccination with attenuated viruses.

22 were vaccinated with a novel avirulent, live attenuated virus (0DeltaNLS) or an adjuvanted glycoprote

23 s derived from a virulent virus and from two attenuated viruses adapted to growth in African green mo

24 n from disease following challenge than live attenuated virus alone.

25 Here, we compared the adaptation of an attenuated virus and its recombinant derivative to that

26 nvestigations into interactions between live attenuated viruses and naturally colonizing bacterial pa

27 ates, including protein-based vaccines, live-attenuated viruses, and gene-based delivery platforms, i

28 Live attenuated viruses are attractive vaccine candidates bec

29 velopment of divalent vaccines based on live attenuated viruses are discussed.

30 Although these attenuated viruses are nonpathogenic in nonhuman primate

31 ies A rotavirus (RVA) vaccines based on live attenuated viruses are used worldwide in humans.

32 ant and the X-defective mutants, possibly as attenuated viruses, are not completely replication defec

33 he vaccine and underscores the nature of the attenuated virus as a vaccine candidate for HSV-1 infect

34 ) T cells in antiviral efficacy using a live-attenuated virus as the vaccine is complicated by the hu

35 letely preventable by i.n. vaccination of an attenuated virus at a low dose and low volume.

36 Similarly attenuated viruses bearing BA.1 and BA.5 spike boost var

37 I (rJHMV(IDelta57-137)) resulted in a highly attenuated virus both in vitro and in vivo that displaye

38 SV-1 challenge following vaccination with an attenuated virus, but multiple factors are involved in c

39 ubella (MMR) and yellow fever (YF) with live attenuated viruses can rarely cause life-threatening dis

40 g influenza virus as a model, we produced an attenuated virus carrying a mammalian-specific miR-93 ex

41 The attenuated viruses completely protected mice against cha

42 Following boosting with live attenuated virus, control of Deltanef replication was su

43 cent data suggest that loss-of-function live-attenuated virus could be a safe lentivirus vaccine.

44 Because replication competent (live) attenuated viruses could over time revert to virulence,

45 virulence study indicated that some of these attenuated viruses could still cause significant levels

46 Infection of swine with the fully attenuated virus did not confer protection against chall

47 om an attenuated strain, L proteins from two attenuated viruses directed the production of up to eigh

48 Compared to wild-type VSV, the highly attenuated virus displayed markedly reduced pathogenesis

49 ) T cell responses elicited by a dengue live attenuated virus (DLAV) vaccine resemble those observed

50 nfection as well as vaccination with live or attenuated viruses elicit tissue resident, CD8(+) memory

51 e applied the previously described synthetic attenuated virus engineering (SAVE) approach to influenz

52 Increased activity of polymerases from attenuated viruses equally affected mRNA transcription a

53 y affect viral replication in vitro, and the attenuated viruses established infection in the brain an

54 In addition, topical immunization with the attenuated virus expressing GM-CSF induced a greater num

55 ompared to parental A/WSN/33 virus and to an attenuated virus expressing the HA and NA genes from A/N

56 pproach is a successful strategy to generate attenuated viruses for future application as vaccines.

57 A primary strategy has been to derive live attenuated viruses for use in intranasally administered

58 studies of NSs and potentially the design of attenuated viruses for vaccination studies.IMPORTANCE SF

59 ocesses can be separated to design effective attenuated viruses for vaccine candidates.

60 za exposure, safety concerns due to its live attenuated virus formulation, and reduced efficacy due t

61 tions (T242N), suggesting the acquisition of attenuated viruses from B57(+) donors.

62 However, this highly attenuated virus generated antibody and T-cell responses

63 e the numbers of passages required to obtain attenuated viruses, genetic modifications introduced int

64 These mammalian-attenuated viruses grow to high titers in insect cells b

65 Attenuated virus growth ability was observed in SHFV mut

66 Mutations introduced into these two residues attenuated virus growth and improved the innate and adap

67 red the HA vRNA replication and reversed the attenuated virus growth phenotype.

68 tivity, affected lipid raft association, and attenuated virus growth.

69 The initial attenuated virus had a tyrosine-to-phenylalanine mutatio

70 w that the subject infected with the NS1-T64 attenuated virus has diminished responses to interferon

71 odeficiency virus (SIV)/macaque system, live attenuated viruses have been shown to provide the best p

72 These attenuated viruses have both copies of gamma(1)34.5 dele

73 Attenuated viruses have proven protective following shor

74 The observed hot spots of variation in the attenuated viruses have the potential to be used in the

75 Analyses such as these of attenuated viruses improve our understanding of the mole

76 reduced virus replication in macrophages and attenuated virus in pigs.

77 mutations in this TR backbone results in an attenuated virus in vitro and in vivo.

78 ce thresholds using mixtures of virulent and attenuated viruses in a transgenic mouse model of poliov

79 Attenuated viruses induced minimal lung injury, diminish

80 unctional CCR5 HIV-1 coreceptor, or a low or attenuated virus inoculum.

81 lt, we show that in tumors infected with the attenuated virus, ionizing radiation increases 13.6-fold

82 a master donor strain to generate other live attenuated viruses is also demonstrated.

83 Cell culture studies have shown that an attenuated virus lacking the viral gamma(1)34.5 genes un

84 to FIMV were compared with responses to live attenuated virus (LAV) and hemagglutinin (H-DNA) vaccine

85 lthough the robust immunity elicited by live-attenuated virus (LAV) vaccine candidates makes them att

86 Vaccination against IBV uses live attenuated viruses (LAVs), generated by multiple passage

87 Live attenuated viruses (LAVs)-those created by passaging a v

88 ion of lysine and arginine residues severely attenuated virus-like particle production, but only the

89 Together, these results demonstrate that our attenuated virus may be a promising nasal vaccine candid

90 Our findings support the concept that attenuated viruses may be the best vaccine option for pr

91 Whereas these rationally attenuated viruses may lead to a new generation of safer

92 is suggests that in mixed viral populations, attenuated viruses may limit the pathogenesis of virulen

93 y, neither T-bet(-/-) mice immunized with an attenuated virus, nor WT mice with Th2 RABV-specific imm

94 Attenuated viruses offer a unique cancer treatment by sp

95 DENV vaccines are based on tetravalent live-attenuated virus platforms.

96 itself is comprised of a heterogeneous live attenuated virus population and thus requires deep-seque

97 as well as the 3' untranslated region, each attenuated virus possessed a different pattern of genomi

98 Intranasal infection of mice with the attenuated viruses primed long-lived T- and B-cell respo

99 igible impact on JFH1 genome replication but attenuated virus production.

100 trate that addition of a DNA prime to a live attenuated virus provided better protection from disease

101 we demonstrate that vaccination with a live-attenuated virus, rendered deficient in RNAi suppression

102 coding sequences of gag derived from a tumor-attenuated virus replaced by those of highly tumorigenic

103 ancer cells is based on the observation that attenuated viruses replicate better in tumor cells than

104 whether mice knocked out for CD80 would show attenuated virus replication following reactivation.

105 murine tracheal epithelial cell cultures and attenuated virus replication, virus spread, the severity

106 n of triphosphorylated viral transcripts and attenuated virus replication, which is rescued by reduci

107 rrangement of spliced segments and that such attenuated viruses represent an excellent option as safe

108 Fully attenuated viruses required at least two genome segments

109 Nasal vaccination with a live attenuated virus results in sustained upregulation of CK

110 uencing and microarrays can therefore detect attenuated virus sequence changes, minority variants, an

111 We recently described a novel attenuated virus, SIVmac-M4, containing multiple mutatio

112 ted rhesus macaques vaccinated with the live attenuated virus SIVmac239Delta3 of CD8+ lymphocytes and

113 In more attenuated viruses, some rabbits died acutely, while oth

114 A clone with the aim of creating potentially attenuated virus stocks.

115 wever, it remains a challenge to identify an attenuated virus strain that has an optimal balance betw

116 the length of time postvaccination with the attenuated virus strain, suggesting a necessary maturati

117 of mouse-adapted SARS-CoV-2, we isolated an attenuated virus that contained a single mutation in a l

118 t of the mutations resulted in significantly attenuated virus that contained greatly decreased levels

119 proteins 1, 15, and 16, results in a highly attenuated virus that does not cause diarrhea in animals

120 virus (TMEV) results in the production of an attenuated virus that grows in baby hamster kidney (BHK)

121 E Modified vaccinia virus Ankara (MVA) is an attenuated virus that is approved as a smallpox vaccine

122 residue from lysine to arginine produces an attenuated virus that is genetically stable and elicits

123 me-encoded PKR inhibitor results in a highly attenuated virus that is immunogenic and protective as a

124 Current vaccines use a live attenuated virus that is usually safe but cannot be give

125 mportant direction for development of highly attenuated viruses that can be applied as live vaccines.

126 e a rational approach for engineering stably attenuated viruses that can serve as safe and effective

127 These attempts led to the production of attenuated viruses that conferred only homologous protec

128 ad to the production of genetically modified attenuated viruses that induce protection in pigs but on

129 pathogenic human CoVs, including the use of attenuated viruses that lack the CoV E protein or expres

130 odels of CoV infection, including the use of attenuated viruses that lack the CoV E protein or expres

131 ch animal populations but often contain live-attenuated viruses that pose risks of reversion to virul

132 ansmission, whereas Pseudomonas lurida MYb11 attenuated virus transmission relative to the standard l

133 nas aeruginosa strains PA01 and PA14 further attenuated virus transmission.

134 irus can be made more robust than the highly attenuated viruses used in clinical trials.

135 ns or following primary DENV serotype 1 live attenuated virus vaccination to determine the antigenic

136 accinate young infants with the current live attenuated virus vaccine (LAV).

137 The traditional live-attenuated virus vaccine approach has been challenging f

138 This finding argues strongly against an attenuated virus vaccine as a solution to the AIDS epide

139 N4), has been identified as a promising live attenuated virus vaccine candidate against disease cause

140 between DENV serotypes in a tetravalent live-attenuated virus vaccine candidate, we analyzed data fro

141 The controversial live attenuated virus vaccine Dengvaxia has boosted the pursu

142 wash specimens of subjects who received live attenuated virus vaccine than in those who received intr

143 and to incorporate the properties of a live attenuated virus vaccine without the inherent safety iss

144 the development and use of an excellent live attenuated virus vaccine, over one million infants and c

145 ulated with a live influenza virus or a live attenuated virus vaccine, prior to challenge, were prote

146 t prove to be useful for inclusion in a live attenuated virus vaccine.

147 ern technology to analyze residual BSA in an attenuated virus vaccine.

148 t the distinct evolutionary dynamics of live attenuated virus vaccines and have important implication

149 Live-attenuated virus vaccines are highly effective in preven

150 Several subunit vaccines and live attenuated virus vaccines are immunogenic and safe in ch

151 ndings provide a pathway for developing live attenuated virus vaccines based on engineering the polym

152 established by immunization with these live attenuated virus vaccines during the first year, despite

153 The usefulness of live attenuated virus vaccines has been limited by suboptimal

154 Live-attenuated virus vaccines provide long-lived protection

155 geting key inflammatory pathways, as well as attenuated virus vaccines, have shown some success in an

156 d-generation Candid#1 vaccine.IMPORTANCELive-attenuated virus vaccines, such as measles/mumps/rubella

157 in animal models or in volunteers receiving attenuated virus vaccines, thereby reducing the efficien

158 plication in vivo and to test LTR mutants as attenuated virus vaccines.

159 e useful, for example, in the development of attenuated virus vaccines.

160 been advocated as a method to generate safe, attenuated virus vaccines.

161 Sequence comparison of tumorigenic and tumor-attenuated virus variants has linked the ability of viru

162 vaccines described above in combination with attenuated virus vectors that express Env.

163 complementation of replication-defective and attenuated viruses via HR with the helper gene provided

164 y gland vs. the PGLNs after inoculation with attenuated virus vs. a nominal protein antigen supports

165 nts, the wild-type-related VSV-G/GFP and two attenuated viruses, VSV-CT1 and VSV-CT9-M51, were compar

166 Vaccination with a live attenuated virus was found to be more efficacious than v

167 ing a lineage tracking system, we found that attenuated virus was highly inhibited in the ability to

168 We found that the attenuated virus was virulent in immunodeficient mice du

169 To generate a highly attenuated virus, we added two reporter genes to the 3'

170 rase subunit, two temperature-sensitive (ts) attenuated viruses were obtained.

171 The attenuated viruses were unstable, and point mutations at

172 We therefore sought to construct novel attenuated viruses with less potential for reversion thr

173 The dSIVs retain characteristics of a live attenuated virus without the drawbacks of potential viru

174 s approach might help to generate human live attenuated viruses without affecting their yield in eggs

175 an influenza virus vaccine based on NS1 live attenuated viruses would confer broad protection against